The Washington Post

Avastin: Why was it pulled, and what are the alternatives?

Genentech’s drug Avastin is displayed in a pharmacy. (JB REED/BLOOMBERG NEWS)

Why did the FDA change course on this drug, and what should the course of action be for patients who had been taking it for this use?

The agency has provided a Q&A on its Web site answering these and other key questions about its decision.

Here are some key excerpts:

“What are the potential risks of taking Avastin?

Women who take Avastin for metastatic breast cancer risk potentially life-threatening or serious side effects, such as bleeding and hemorrhaging; heart attack or heart failure; severe blood pressure; and the development of perforations in different parts of the body such as the nose, stomach and intestines.”

“When does this labeling change become effective?

The approval for metastatic breast cancer is being withdrawn immediately.”

“What should patients do who are currently being treated with Avastin for their breast cancer?

Patients currently receiving Avastin for breast cancer should speak with their oncologists (cancer physicians) about whether to continue their treatment or explore other treatment options. Oncologists should use their medical judgment when deciding whether their patients should continue using Avastin with the drug paclitaxel, take paclitaxel alone, or consider other treatment options.”


The full text of the FDA’s Q&A is available here.

Related stories:

FDA revokes approval for Avastin

Experimental breast cancer vaccine shows promise

Imperfect cancer screenings spark angst

Sarah Halzack is The Washington Post's national retail reporter. She has previously covered the local job market and the business of talent and hiring. She has also served as a Web producer for business and economic news.

The Freddie Gray case

Please provide a valid email address.

You’re all set!

Campaign 2016 Email Updates

Please provide a valid email address.

You’re all set!

Get Zika news by email

Please provide a valid email address.

You’re all set!
Show Comments
Most Read

Success! Check your inbox for details.

See all newsletters

Close video player
Now Playing